MDB Capital Holdings, LLC Class A common

The transcript did not include revenue, EPS, gross margin, or year-over-year financial figures. Management said the first half included two transactions, and Ticketplus closed right after the end of the second quarter; those deals helped offset some overhead. Looking ahead, management said Public Ventures could see a partnership or sale in the next quarter, PatentVest is being prepared for an independent financing, Paulex Bio is expected to get close to an IPO in the fourth quarter of this year, and eXoZymes may see commercial partnerships soon; the company also said it is aiming to bring its platform down to about $6 million in total operational expenses after planned actions.

Chris Marlett sounded defensive about the stock but constructive about the portfolio, saying MDB is not happy with the share price yet still believes in the platform and the companies it has built. He argued the microcap market is neglected, money is concentrated in a few large names, and capital is rotating away from small companies, but he thinks that can eventually help MDB’s segment if attention returns. Strategically, he emphasized “leverage without dilution,” a lean operating model, and focusing on value inflection points rather than aggressive new launches.

No CFO prepared remarks were provided in the transcript. The financial commentary came from Chris Marlett, who said MDB wants to reduce platform costs to about $5 million to $6 million a year and offset expenses with fees from transactions. He also said the first half’s two transactions, including Ticketplus, helped offset overhead, and that spinouts/partnerships could reduce MDB’s need to fund PatentVest and potentially other assets.

In Q&A, George Brandon asked how MDB is helping portfolio companies realize value and how the company is getting its story out to shareholders. Marlett said MDB is spending real time on commercialization support, especially at eXoZymes, and is trying to connect companies with contacts and simplify their stories for investors. On HeartBeam, he said the technology could be transformative but the better path is partnerships rather than a capital-intensive solo launch; on eXoZymes, he said a smaller-than-hoped financing can be helpful if the company manages dilution and uses spinouts, strategic investments, or commercial deals to reach a value inflection point.